WO1998047521A1 - Phages, methods for growing and detecting them and their use - Google Patents

Phages, methods for growing and detecting them and their use Download PDF

Info

Publication number
WO1998047521A1
WO1998047521A1 PCT/US1998/007395 US9807395W WO9847521A1 WO 1998047521 A1 WO1998047521 A1 WO 1998047521A1 US 9807395 W US9807395 W US 9807395W WO 9847521 A1 WO9847521 A1 WO 9847521A1
Authority
WO
WIPO (PCT)
Prior art keywords
phage
animal
bacterium species
bacterium
phages
Prior art date
Application number
PCT/US1998/007395
Other languages
French (fr)
Inventor
Philip A. Youderian
Carolyn H. Bohach
Original Assignee
Idaho Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idaho Research Foundation, Inc. filed Critical Idaho Research Foundation, Inc.
Priority to AU71133/98A priority Critical patent/AU7113398A/en
Publication of WO1998047521A1 publication Critical patent/WO1998047521A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10311Siphoviridae
    • C12N2795/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention pertains to phages, methods of growing phages, and to methods of utilizing phages for reducing concentrations of bacterium species pathogenic to humans.
  • the invention further pertains to methods for producing plants, meat and dairy products for human consumption. Additionally, the invention pertains to methods of detecting bacterial strains.
  • E. coli O 157:H7 can cause human disease . It is thought that in the overwhelming majority of E. coli O 157:H7 outbreaks the source of infection is contaminated ruminant (primarily bovine) food products, either under-cooked beef or unpasteurized dairy products. Disease, however, is not limited to those who eat contaminated food. For example, one of the children who died in the above-mentioned outbreak on the West Coast apparently never ate at a restaurant chain serving contaminated meat, but instead played with an infected child.
  • Hemolytic uremic syndrome is a dangerous disease . At the first outward signs of disease , the kidney damage is frequently already done. Even those who receive immediate, modern medical attention are not guaranteed recovery. Accordingly, it would be desirable to develop procedures for reducing the likelihood of E. coli 0157:H7 infection in humans. Particularly, it would be desirable to develop procedures for reducing E. coli 0157:H7 contamination of food products. More generally, it would be desirable to develop procedures for reducing E. coli 0157:H7 contamination on surfaces from which the bacteria may be transferred to human beings.
  • E. coli 0157:H7 is often found in ruminant mammals. Ruminant mammals are common in our environment and comprise farm animals, such as cattle and sheep, and wild animals, such as deer. Although E. coli O 157:H7 causes disease in humans, it is frequently not harmful to ruminant mammals. In fact, E. coli 0157:H7 may be a common transient member of the intestinal flora of many ruminant mammals. E. coli 0157:H7 likely also exists in the digestive tracts of other animals besides ruminant mammals. For instance, E. coli 0157:H7 is thought to be exist in the digestive tracts of birds, including poultry, and may also exist in pigs. Additionally, E.
  • E. coli 0157:H7 appears to be substantially pervasive in the environment beyond animal digestive tracts, with unpasteurized apple juice even occasionally being contaminated with pathogenic quantities of E. coli 0157:H7.
  • E. coli 0157:H7 in cattle feces and intestinal tracts can find its way into humans through a number of routes. For instance, cattle can carry E. coli 0 157:H7 into meat processing plants. Once inside a meat processing plant, the bacteria can be introduced onto meat if there is contact of meat surfaces with animal feces, or with surfaces which have come in contact with animal feces. Additionally, it appears that E. coli 0157:H7 can be transferred from an animal's haircoat, or from surfaces which have contacted an animal's haircoat.
  • E. coli 0157:H7 can be transferred by aerosols formed, for example, when a surface having E. coli 0157:H7 thereon is sprayed with a liquid, such as water. If a food product becomes contaminated with E. coli 0157:H7, detection of the contamination can be difficult. As discussed above, only very small numbers of E. coli 0157:H7 need be ingested by a human to cause disease . Such low numbers are hard to detect. Accordingly, it would be desirable to reduce the likelihood of contamination of food products by E. coli 0157:H7, rather than rely on detection techniques to identify contaminated food products. It is noted that one method of ridding beef, dairy and other food products of E.
  • coli 0157:H7 is to heat-treat the food products to kill the bacteria.
  • E. coli 0157:H7 cause widespread human disease.
  • pathogenic E. coli 0111 strains are common in New Zealand and Australia, and cause human symptoms similar to those of E. coli 0157:H7 infection.
  • pathogenic Salmonella strains are ubiquitous in the environment. Such pathogenic Salmonella strains include, for example, S. enteriditis, S. typhi, S. paratyphi, S. dublin, S. cholerasuis, and S. pullorum.
  • a first step of the method comprises collecting animal excrement, such as feces.
  • the excrement may be collected by, for example, gathering manure at a farm.
  • the next step of the method is to obtain a phage lethal to a selected bacterium species from the animal excrement.
  • a method of obtaining such phage is to procure a mix of phages from the animal excrement and subject the phages to growth conditions which selectively grow those which can utilize the selected bacterium species as a host. For example , phages selectively lethal toward E. coli 0157:H7 can be obtained by the following phage detection and isolation procedure .
  • a culture comprising 5 mis of E. coli 0157:H7 at an exponential growth phase .
  • the E. coli is preferably in Luria broth (Luria broth is described in Molecular Cloning - a Laboratory Manual ( 1989) 2nd edition, edited by Sambrook J ., Fritsch ⁇ .F., and Maniatis T., Cold Spring Harbor Laboratory Press, New York.) with 10 mM MgSO ⁇ .
  • the culture is inoculated with 0.5 gm of a fecal sample.
  • the exponentially growing culture is inoculated with a material collected from a non-sterile environment.
  • the fecal sample can be placed directly into the exponentially growing E. coli without any purification occurring after collecting the fecal sample.
  • the culture is grown for 12 hours at 37° C.
  • the culture is then spun in a low-speed centrifuge to precipitate the bacteria while leaving the phages in a supernatant.
  • the supernatant is treated with chloroform (about 1 part chloroform to 20 parts solution, by volume) to kill any bacteria remaining in the supernatant.
  • Aliquots of 0.1 ml to 0.5 ml are removed from the supernatant and spread on lawns of E. coli 0157:H7.
  • the lawns are prepared by a soft-agar overlay technique described by Adams. (See, Adams, M. H . ( 1959) Bacteriophages, Interscience Publishers, New York.)
  • a plaque will form.
  • Lethal phages can be removed from the plaque and used to grow a high-titer (concentration) phage stock by methods known to persons of ordinary skill in art. Such methods can include, for example, the following process. A plug of a plaque is removed and resuspended in 1 ml of Luria broth containing 1 mM MgSO ⁇ Aliquots of 0.1 ml to 0.5 ml of the resuspended plaque material are utilized to infect cultures containing 30-300 mis of E.
  • coli 0157:H7 at an exponential growth phase in Luria broth containing 1 mM MgSO ⁇
  • the cultures are grown for 6-18 hours at 37° C and then spun in a low-speed centrifuge to precipitate the bacteria while leaving the lethal phages in a supernatant.
  • the supernatant is treated with chloroform (about 1 part chloroform to 20 parts solution, by volume) to kill any bacteria remaining in the supernatant.
  • the lethal phages can then be assayed on one or more non-0157 strains of E. coli, such as, for example, 091 strains, 05 strains and 0111 strains, to determine if the lethal phages are selectively lethal to 0157 strains of E. coli.
  • Phages which are selectively lethal to 0157 strains of E. coli are preferred for removing E. coli 0157:H7 from ruminant digestive tracts. Such phages are unlikely to disrupt ruminant digestion by destroying microbial flora other that E. coli 0157:H7.
  • Table 1 shows results obtained from subjecting 53 fecal samples to the above-described procedure.
  • the 53 samples were collected from five different farms in Idaho and Washington. As shown, the fecal samples yielded five phages, labeled 1-5.
  • the phages labeled 1 , 3, 4, and 5 were lethal for E. coli 0157 strains and not for 091 strains, 05 strains and 0111 strains of E. coli.
  • Table 2 illustrates growth patterns obtained from the phages identified as 1 , 3, 4, and 5 in Table 1.
  • the phages yielded three different patterns of growth on eight independent, different 0157 isolates.
  • the different 0157 isolates were:
  • phages such as those described with reference to Tables 1 and 2 are further subjected to conditions selective for growth at 50° C to isolate temperature-stable, spontaneous mutants of the phages.
  • the phage labeled 4 in Table 1 was temperature- treated at 50° C by the following procedure.
  • coli 0157:H7 in Luria broth containing 10 mM MgS0 4 , and grown for 6-18 hours in a procedure similar to that described above for isolating phages lethal to E. coli 0157:H7. Phages were removed from the E. coli 0157:H7 culture by spinning the bacteria from the culture and applying chloroform to the supernatant to kill any remaining bacteria. The phages were then resubjected to temperature treatment at 50 °C for 2 hours. The processes of temperature treatment and growth of the phages were repeated until the phages had been subjected to four total temperature treatments at 50 °C for 2 hours each.
  • the temperature-stable phage ER4hrl is substantially fully stable to exposure to a temperature of 50 °C for 2 hours. This in sharp contrast to the phage 4 of Table 1 from which ER4hrl was derived. Phage 4 would typically lose about 90% of its activity after 2 hours of exposure to a temperature of 50 °C.
  • ER4hrl is also stable for relatively prolonged exposure to pH extremes of 0 to 11. Whereas phage 4 would lose about 90% of its activity after 2 hours of exposure to a pH of either 0 or 11, ER4hrl loses almost no activity during the same amount of exposure to the same pH's.
  • ER4hrl could advantageously prolong the useful life of the phage in an animal's digestive tract.
  • pH and temperature stability of ER4hrl could advantageously extend the available methods for transporting ER4hrl. For instance, ER4hrl may better withstand the temperature extremes of unrefrigerated rail-car or truck transport than a phage that had not been temperature treated. Specifically, phages which are temperature treated may be able to better withstand storage at temperatures of 30° C or higher for longer periods than phages which are not temperature treated.
  • the phages obtained from animal excrement are utilized to reduce a concentration of a bacterium species.
  • Methods by which the phages may be utilized to reduce a concentration of a bacterium species include, for example, applying the phages to surfaces to kill bacterium species on such surfaces.
  • the phages may be inserted into an animal's digestive tract to reduce a concentration of a bacterium species within the digestive tract. Particular embodiments of the present invention are discussed with reference to Figs. 2-5.
  • Mass 10 comprising a phage is fed to an animal 12 by a handler 14.
  • Mass 10 could comprise, for example, a liquid-filled capsule comprising phages in a liquid medium, or a solid comprising desiccated phages. If the phages are in a liquid medium, the phages can be in, for example, a buffered saline solution comprising about 10 mM MgSO ⁇
  • animal 12 is a ruminant, such as a cow
  • mass 10 comprises phages selectively lethal to E. coli 0157:H7, such as the phage identified in our lab as ⁇ R4hrl , and identified by ATCC No. 55952.
  • Ingestion of mass 10 by animal 12 inserts the phages into a digestive tract of animal 12.
  • the phages are selectively lethal to E. coli 0157:H7
  • E. coli 0157:H7 the phages will reduce the concentration of E. coli 0157:H7 within the digestive tract of animal 12 without significantly reducing concentrations of other bacteria within the animal's digestive tract. This can advantageously rid an animal of E. coli 0157:H7 without adversely affecting the animal's digestive processes.
  • Mass 10 can comprise a controlled dosage of a phage .
  • Alternative methods for administering a controlled dosage of a phage to an animal are recognized by persons of ordinary skill in the art, and would include, for example, pouring a dose of a liquid into the mouth of animal 12.
  • a phage could be inserted into a digestive tract of animal 12 by methods other than administering a controlled dosage to animal 12.
  • a phage solution 40 is applied to an animal's feed 42.
  • Phage solution 40 will preferably comprise a buffered saline solution, and will more preferably comprise a buffered saline solution containing about 10 mM MgSO ⁇
  • Alternative methods for applying phages to feed 42 will be recognized by persons of ordinary skill in the art and include, for example, dusting freeze-dried phages onto the feed.
  • the phage is shown applied only to a top surface of feed 42, the invention encompasses methods wherein the phage is mixed into feed 42 during or after application to the feed.
  • feed 42 is ingested by an animal 44, thus inserting phages into animal 44.
  • a method of the present invention was reduced to practice in an experiment summarized in Table 3.
  • a phage obtained from cattle (genus Bos) feces was utilized to reduce E. coli 0157:H7 concentrations in a digestive tract of a sheep (genus Ovis).
  • the experiment comprised infecting two healthy year-old Suffolk ewes with 4 x 10 10 E. coli 0157:H7 strain ATCC 43894 utilizing a procedure described by Kudva et. al. (See, Kudva I. T., Hatfield, P. G ., and Hovde C. J . ( 1995) Applied and Environmental Micro. Vol. 61, pg.
  • the ewes were orally inoculated with a 20 ml overnight culture of ATCC 43894 in Luria broth using a 20 ml sterile syringe cartridge (no needle).
  • One of the ewes was designated an experimental animal and the other a control animal.
  • the two ewes were maintained on an alfalfa-hay diet throughout the course of the experiment and penned separately.
  • Fecal samples ( 10 gm) were taken at 24 hour intervals for 12 days from both the control animal and the experimental animal. The fecal samples were assayed for the presence of E. coli 0157:H7 before and after enrichment for E. coli 0157:H7, utilizing a procedure described by Kudva et. al. Also, the fecal samples from the experimental animal were assayed for the presence of phage ER4hrl . The procedure utilized for assaying for ER4hrl was as follows. Feces ( 1 gm) were suspended in 10 ml of Luria broth containing 10 mM MgSC>4 with a vortex mixer.
  • the resuspended feces were maintained at 40 °C for 2-4 hours, then spun in a low speed centrifuge to pellet the bacteria and particulate matter, and form a supernatant. Chloroform was added to the supernatant and the supernatant was then filtered through a 0.45 micron filter. About 0.5 ml of the supernatant was plated on a lawn of E. coli 0157:H7 to quantitate the amount of phage present.
  • Day 0 corresponds to the day on which E. coli were fed to the sheep
  • Day 2 corresponds to the day on which phages were fed to the experimental animal.
  • the data shows that the experimental animal cleared E. coli 0157:H7 from its digestive tract four days earlier than the control animal cleared E. coli 0157:H7 from its digestive tract. Clearance of E. coli 0157:H7 from the experimental animal was concomitant with the appearance of phage in the fecal material of the experimental animal, indicating that the phages were responsible for the clearance of E. coli 0157:H7. Also, more phages came out of the experimental animal than had been put into the experimental animal, indicating that the phages had multiplied within the experimental animal.
  • E. coli 0157 strains are naturally cleared from animal systems and then reestablished in the animal systems, phages specific for E. coli 0157 strains are expected to also be cleared from animal systems after a period of time. Accordingly, such phages may have to be reintroduced into animal digestive tracts at regular intervals to keep the animals clear of E. coli 0157 strains.
  • animals could be cleared of E. coli 0157 strains and at the same time the animals' pens could be cleared of E. coli 0157 by applying phages within the animals' pens.
  • the present invention encompasses methods in which phages are obtained, for example, from fecal samples of an animal which is to have phages inserted within it; from fecal samples of an animal of the same genus as the animal which is to have phages inserted within it; or from fecal samples of an animal of a different genus than the animal which is to have phages inserted within it.
  • Fig. 5 illustrates an animal carcass 20 being sprayed with a phage solution 22 by a worker 24 in a meat processing plant.
  • Phage solution 22 is preferably lethal to a bacterium species pathogenic to humans.
  • Application of phage solution 22 to surfaces within the meat processing plant, including animal carcass 20 and surfaces with which animal carcass 20 may come in contact, can reduce a risk of human ingestion of the pathogenic bacterium species. If the phage and a bacterium pathogenic to humans come into proximity with one another, the phage can infect and kill the bacterium.
  • the phage solution can be applied to surfaces either before or after pathogenic bacterium species contact the surface. Also, a phage applied to a surface may leave the surface and ultimately contact a bacterium pathogenic to humans someplace other than the surface.
  • phage solution 22 comprises a phage specific for E. coli 0157:H7, such as the phage ER4hrl, identified by the ATCC No. 55952.
  • phage ER4hrl a phage specific for E. coli 0157:H7
  • phage ER4hrl identified by the ATCC No. 55952.
  • Application of phage ER4hrl to meat surfaces and to surfaces with which the meat may come in contact can reduce a likelihood of the meat leaving the processing plant contaminated with E. coli 0157:H7.
  • Application of the phage ER4hrl can thus reduce a likelihood of human ingestion of pathogenic E. coli 0157 strains.
  • the present invention encompasses methods beyond those shown in Figs. 2-5.
  • the method of the present invention encompasses general methods of reducing concentrations of bacterium species on human food items by applying phages lethal to such bacterium species onto surfaces of the food items.
  • the present invention encompasses methods for producing dairy products for human consumption in which an animal is milked to produce a dairy product, and phages lethal to a bacterium species are applied to the dairy product.
  • Such methods encompass application of phages to a dairy product to reduce concentrations of pathogenic E. coli 0157 strains within the dairy product.
  • the phages could comprise, for example, ER4hrl .
  • the invention further encompasses methods for producing meat for human consumption.
  • Such methods can include inserting a phage lethal to a pathogenic bacterium species into a digestive tract of an animal prior to slaughtering the animal.
  • the methods can further include, after slaughtering the animal, applying the phage to the meat obtained from slaughter to help insure that the meat is not contaminated with pathogenic bacterium species introduced onto the meat through mishandling during or after slaughter.
  • the animals shown in Figs. 2, 3 and 5 are ruminants, it is to be understood that the method of the present invention can be used for treating any animal, including, for example, swine and poultry.
  • the invention further encompasses methods of utilizing phages for reducing pathogenic Salmonella contamination of food products, such as, for example, poultry products.
  • phages could be obtained from, for example, poultry manure.
  • the invention encompasses methods of utilizing phages for reducing pathogenic bacterial contamination of plant products, such as, for example, fruit and vegetable products.
  • plant products such as, for example, fruit and vegetable products.
  • An example fruit product is apple juice.
  • An example vegetable product is lettuce leaves.
  • leaf lettuce was inoculated with E. coli 0157:H7 by submerging the leaves in a saline solution having 10 colony forming units (cfu) of E. coli 0157:H7 per ml.
  • the leaf lettuce was incubated in the saline solution for 10 minutes, which resulted in approximately 10 cfu being deposited per gram of lettuce.
  • SM Sepension Medium comprising 0.1 M NaCl; 0.01 M Mg(S0 4 ); 2% gelatin; and 1 M Tris-HCl, pH 7.5
  • the SM with phage contained 10 plaque -forming units (pfu) of the 0157-specific phage ER4hrl .
  • the lettuce leaves incubated with phage had 10-fold less E. coli 0157:H7 than did the control lettuce leaves.
  • 1000 times less E. coli 0157:H7 was present in the SM having phage than in the control SM.
  • the invention further encompasses methods of utilizing phages for specific identification of bacterial pathogens.
  • phages labeled 1, 3, 4 and 5 in Table 1 are relatively specific for utilizing E. coli 0157 strains as hosts, such phages may be used to identify the presence of E. coli 0157 strains.
  • ⁇ R4hrl is also relatively specific for utilizing E. coli 0157 strains as hosts, and can therefore also be utilized to identify E. coli 0157:H7 strains.
  • the method of Bonner and Cliver is an in vitro method for detecting E. coli 0157:H7.
  • the present invention encompasses an in vivo method for detecting E. coli 0157:H7.
  • the invention encompasses a method wherein a phage specific for E. coli 0157:H7 is inserted into an animal's digestive tract and the animal's feces are subsequently monitored to determine if the phage multiplies within the animal. If the phage multiplies, more phage will come out of the animal then was inserted into the animal. If the phage is specific for E. coli 0157:H7, such multiplication of the phage within the animal will indicate the presence of E. coli 0157:H7 within the animal.
  • An advantage of the in vivo method of the present invention over the in vitro method of Bonner and Cliver is that the method of the present invention can eradicate E. coli 0157:H7 from an animal while the method is being utilized to detect E. coli 0157:H7.
  • the method can provide information that an animal is carrying E. coli 0157:H7 and, in a common step, reduce a concentration of E. coli 0157:H7 within the animal.
  • the above-described method of in vivo detection can be utilized for other pathogens in addition to E. coli 0157:H7.
  • the method can be utilized for detection of E. coli 0111 strains, and Salmonella strains, including, for example, S. enteritidis, S. typhi, S. paratyphi, S. d blin, S. cholerasuis , and S. pullorum .
  • the invention further encompasses methods in which phages are utilized in increasingly high concentrations to compensate for natural selection of bacteria resistant to the phages.
  • a phage could be administered to an animal at a first dose to reduce a concentration of a bacterial strain within the animal.
  • the phage could be readministered to the animal at a second dose to reduce a concentration of the bacterial strain that may have reestablished in the animal.
  • the second dose could be at the same concentration as the first dose, a lower concentration than the first dose, or a higher concentration than the first dose.
  • the second dose will be at a higher concentration than the first dose.
  • the doses of phage could comprises mixtures, either solid or liquid, containing the phage at desired concentrations.
  • the invention further encompasses methods in which two or more genetically different phages are utilized, either sequentially or simultaneously, to reduce concentrations of one or more pathogenic bacteria. For instance, at least two genetically different phages selective for E. coli 0157:H7 could be mixed to form a phage cocktail.
  • the genetically different phages could comprise, for instance, two of the phages labeled 1, 4 or 5 in tables 1 and 2. (The phage labeled 3 was not included in the list of genetically different phages because the phage labeled 3 showed the same growth patterns as the phage labeled 1 in the experiment summarized in Table 2.
  • the phage cocktail could then be inserted within an animal's digestive tract to substantially simultaneously insert the at least two different phages.
  • the at least two different phages could be inserted sequentially, with one of the phages being inserted first, a period of time passing, and then another of the phages being inserted.
  • Two or more different phages could also be applied, either simultaneously or sequentially, to one or more surfaces to reduce a concentration of a bacterium species pathogenic to humans. For instance, two or more different phages could be applied to one or more surfaces in a meat processing plant.
  • Utilization of two or more different phages in a method for reducing a concentration of a bacterial strain can have advantages over methods which utilize only one phage. For instance, bacterial strains are less likely to develop resistance to a cocktail comprising two or more different phages then to develop resistance to a single phage. Further, if two or more different phages are applied sequentially, rather than simultaneously, a later-applied phage can remain lethal to bacteria which have developed a resistance to an earlier-applied phage.
  • the invention encompasses methods of protecting phages from ultraviolet light prior to, and during, utilization of the phages to destroy pathogenic bacteria.
  • Methods for protecting the phages from ultraviolet light can include, for example, storing the phages in containers which are relatively ultraviolet-light-impermeable, applying the phages to animal feed in darkened areas, and incorporating the phages within capsules having relatively ultraviolet-light-impermeable outer casings.

Abstract

The invention encompasses phages, methods of growing phages, methods of utilizing phages for reducing concentrations of bacterium species pathogenic to humans, and methods for detecting bacterial strains. The invention further encompasses methods for producing meat and dairy products for human consumption. In one aspect, the invention includes a method for producing meat for human consumption comprising the following steps: a) inserting a phage lethal to a bacterium species into a digestive tract of an animal to reduce a concentration of the bacterium species within the digestive tract; and b) slaughtering the animal to produce meat for human consumption. In another aspect, the invention includes a method for producing meat for human consumption comprising the following steps: a) slaughtering an animal to produce meat; and b) applying a phage lethal to a bacterium species to the meat. In yet another aspect, the invention includes a method for selectively reducing a concentration of a bacterium species pathogenic to humans which is a natural part of the bacterial flora of an animal digestive tract comprising the following steps: a) collecting animal excrement; b) obtaining a phage lethal to the bacterium species from the animal excrement; and c) applying the phage lethal to the bacterium species to a surface from which bacteria could contact humans to reduce a concentration of the bacterium species pathogenic to humans on said surface.

Description

PHAGES, METHODS FOR GROWING AND DETECΗNG THEM AND THEIR USE
Technical Field
The invention pertains to phages, methods of growing phages, and to methods of utilizing phages for reducing concentrations of bacterium species pathogenic to humans. The invention further pertains to methods for producing plants, meat and dairy products for human consumption. Additionally, the invention pertains to methods of detecting bacterial strains. Background Art
In 1993 an outbreak of food poisoning occurred in the Western United States. The outbreak was eventually linked to a coliform, E. coli O 157:H7, that had been served in contaminated, under-cooked hamburger at various restaurants. In July of 1996, more than 10,000 people in Japan were stricken by a serious outbreak of food poisoning traced tentatively to daikon radish spouts contaminated by E. coli 0157:H7, at least seven died. It is estimated that between 10,000 and 20,000 human infections with E. coli 0157:H7 occur annually in the United States. Enterohemorrhagic strains of E. coli (EHEC), especially those of the serotype 0157:H7, can cause human hemorrhagic colitis (bloody diarrhea) . Approximately 2-7 % of infections progress to hemolytic uremic syndrome, which is characterized by anemia, thrombocytopenia, kidney failure, and a death rate of 3-5 % . Unlike many pathogenic bacteria, ingestion of very few, sometimes less than 20, E. coli O 157:H7 can cause human disease . It is thought that in the overwhelming majority of E. coli O 157:H7 outbreaks the source of infection is contaminated ruminant (primarily bovine) food products, either under-cooked beef or unpasteurized dairy products. Disease, however, is not limited to those who eat contaminated food. For example, one of the children who died in the above-mentioned outbreak on the West Coast apparently never ate at a restaurant chain serving contaminated meat, but instead played with an infected child.
Hemolytic uremic syndrome is a dangerous disease . At the first outward signs of disease , the kidney damage is frequently already done. Even those who receive immediate, modern medical attention are not guaranteed recovery. Accordingly, it would be desirable to develop procedures for reducing the likelihood of E. coli 0157:H7 infection in humans. Particularly, it would be desirable to develop procedures for reducing E. coli 0157:H7 contamination of food products. More generally, it would be desirable to develop procedures for reducing E. coli 0157:H7 contamination on surfaces from which the bacteria may be transferred to human beings.
E. coli 0157:H7 is often found in ruminant mammals. Ruminant mammals are common in our environment and comprise farm animals, such as cattle and sheep, and wild animals, such as deer. Although E. coli O 157:H7 causes disease in humans, it is frequently not harmful to ruminant mammals. In fact, E. coli 0157:H7 may be a common transient member of the intestinal flora of many ruminant mammals. E. coli 0157:H7 likely also exists in the digestive tracts of other animals besides ruminant mammals. For instance, E. coli 0157:H7 is thought to be exist in the digestive tracts of birds, including poultry, and may also exist in pigs. Additionally, E. coli 0157:H7 appears to be substantially pervasive in the environment beyond animal digestive tracts, with unpasteurized apple juice even occasionally being contaminated with pathogenic quantities of E. coli 0157:H7. E. coli 0157:H7 in cattle feces and intestinal tracts can find its way into humans through a number of routes. For instance, cattle can carry E. coli 0 157:H7 into meat processing plants. Once inside a meat processing plant, the bacteria can be introduced onto meat if there is contact of meat surfaces with animal feces, or with surfaces which have come in contact with animal feces. Additionally, it appears that E. coli 0157:H7 can be transferred from an animal's haircoat, or from surfaces which have contacted an animal's haircoat. Further, it appears that E. coli 0157:H7 can be transferred by aerosols formed, for example, when a surface having E. coli 0157:H7 thereon is sprayed with a liquid, such as water. If a food product becomes contaminated with E. coli 0157:H7, detection of the contamination can be difficult. As discussed above, only very small numbers of E. coli 0157:H7 need be ingested by a human to cause disease . Such low numbers are hard to detect. Accordingly, it would be desirable to reduce the likelihood of contamination of food products by E. coli 0157:H7, rather than rely on detection techniques to identify contaminated food products. It is noted that one method of ridding beef, dairy and other food products of E. coli 0157:H7 is to heat-treat the food products to kill the bacteria. However, as it is inconvenient to fully cook all food products before ingestion, and as it is unlikely that all dairy and fruit juice products have been properly pasteurized, it would be desirable to develop alternative methods of reducing the likelihood of E. coli 0157:H7 contamination in meat, dairy and other food products.
It is also noted that other bacteria besides E. coli 0157:H7 cause widespread human disease. For instance, pathogenic E. coli 0111 strains are common in New Zealand and Australia, and cause human symptoms similar to those of E. coli 0157:H7 infection. As another example, pathogenic Salmonella strains are ubiquitous in the environment. Such pathogenic Salmonella strains include, for example, S. enteriditis, S. typhi, S. paratyphi, S. dublin, S. cholerasuis, and S. pullorum. Pathogenic Salmonella strains are frequently found in the digestive systems of poultry, such as chickens and turkey, and frequently cause food poisoning. It would be desirable to develop methods applicable to many types of pathogenic bacteria for reducing the likelihood of the pathogenic bacteria being ingested by humans. Best Modes for Carrying Out the Invention and Disclosure of Invention A block diagram of a method of the present invention is illustrated in
Fig. 1. A first step of the method comprises collecting animal excrement, such as feces. The excrement may be collected by, for example, gathering manure at a farm.
The next step of the method is to obtain a phage lethal to a selected bacterium species from the animal excrement. A method of obtaining such phage is to procure a mix of phages from the animal excrement and subject the phages to growth conditions which selectively grow those which can utilize the selected bacterium species as a host. For example , phages selectively lethal toward E. coli 0157:H7 can be obtained by the following phage detection and isolation procedure .
A culture is prepared comprising 5 mis of E. coli 0157:H7 at an exponential growth phase . The E. coli is preferably in Luria broth (Luria broth is described in Molecular Cloning - a Laboratory Manual ( 1989) 2nd edition, edited by Sambrook J ., Fritsch Ε .F., and Maniatis T., Cold Spring Harbor Laboratory Press, New York.) with 10 mM MgSO^. The culture is inoculated with 0.5 gm of a fecal sample. Thus, the exponentially growing culture is inoculated with a material collected from a non-sterile environment. The fecal sample can be placed directly into the exponentially growing E. coli without any purification occurring after collecting the fecal sample. After the inoculation, the culture is grown for 12 hours at 37° C. The culture is then spun in a low-speed centrifuge to precipitate the bacteria while leaving the phages in a supernatant. The supernatant is treated with chloroform (about 1 part chloroform to 20 parts solution, by volume) to kill any bacteria remaining in the supernatant. Aliquots of 0.1 ml to 0.5 ml are removed from the supernatant and spread on lawns of E. coli 0157:H7. The lawns are prepared by a soft-agar overlay technique described by Adams. (See, Adams, M. H . ( 1959) Bacteriophages, Interscience Publishers, New York.)
If a phage lethal to E. coli 0157:H7 is present, a plaque will form. Lethal phages can be removed from the plaque and used to grow a high-titer (concentration) phage stock by methods known to persons of ordinary skill in art. Such methods can include, for example, the following process. A plug of a plaque is removed and resuspended in 1 ml of Luria broth containing 1 mM MgSO^ Aliquots of 0.1 ml to 0.5 ml of the resuspended plaque material are utilized to infect cultures containing 30-300 mis of E. coli 0157:H7 at an exponential growth phase in Luria broth containing 1 mM MgSO^ The cultures are grown for 6-18 hours at 37° C and then spun in a low-speed centrifuge to precipitate the bacteria while leaving the lethal phages in a supernatant. The supernatant is treated with chloroform (about 1 part chloroform to 20 parts solution, by volume) to kill any bacteria remaining in the supernatant. The lethal phages can then be assayed on one or more non-0157 strains of E. coli, such as, for example, 091 strains, 05 strains and 0111 strains, to determine if the lethal phages are selectively lethal to 0157 strains of E. coli. Phages which are selectively lethal to 0157 strains of E. coli are preferred for removing E. coli 0157:H7 from ruminant digestive tracts. Such phages are unlikely to disrupt ruminant digestion by destroying microbial flora other that E. coli 0157:H7.
The phage detection and isolation procedure described above yielded the results shown in Table 1. Specifically, Table 1 shows results obtained from subjecting 53 fecal samples to the above-described procedure. The 53 samples were collected from five different farms in Idaho and Washington. As shown, the fecal samples yielded five phages, labeled 1-5. The phages labeled 1 , 3, 4, and 5 were lethal for E. coli 0157 strains and not for 091 strains, 05 strains and 0111 strains of E. coli.
Table 1
Figure imgf000007_0001
Table 2 illustrates growth patterns obtained from the phages identified as 1 , 3, 4, and 5 in Table 1. The phages yielded three different patterns of growth on eight independent, different 0157 isolates. The different 0157 isolates were:
0157 isolate 1 = ATCC 43894
O 157 isolate 2 = ATCC 43889 0157 isolate 3 = ATCC 43890
O 157 isolate 4 = 549-9-LIII
0157 isolate 5 = 9024-1-LIII
0157 isolate 6 = 5019-13-LIII
0157 isolate 7 = G6001 O 157 isolate 8 = 35150 The data of Table 2 reflects the relative ability of a particular phage stock to clear a lawn of each host bacterium. Phage stocks were diluted by serial 10-full dilutions and spotted on lawns of each type of indicator cells. Each "plus" indicates the number of serial 10-full dilutions that still allowed a phage stock to form clearings, or plaques, on a particular indicator lawn. The patterns are not due to the bacteria overcoming phage infection through host restriction/modification.
Table 2
Figure imgf000008_0001
In one embodiment of the present invention, phages, such as those described with reference to Tables 1 and 2, are further subjected to conditions selective for growth at 50° C to isolate temperature-stable, spontaneous mutants of the phages. For instance, the phage labeled 4 in Table 1 was temperature- treated at 50° C by the following procedure. The phage, in Luria broth with 10 mM MgSO^, was maintained at 50 °C for two hours. Subsequently, the phage was inoculated into a culture of exponentially growing E. coli 0157:H7, in Luria broth containing 10 mM MgS04, and grown for 6-18 hours in a procedure similar to that described above for isolating phages lethal to E. coli 0157:H7. Phages were removed from the E. coli 0157:H7 culture by spinning the bacteria from the culture and applying chloroform to the supernatant to kill any remaining bacteria. The phages were then resubjected to temperature treatment at 50 °C for 2 hours. The processes of temperature treatment and growth of the phages were repeated until the phages had been subjected to four total temperature treatments at 50 °C for 2 hours each. Such processing yielded a temperature-stable phage referred to in our labs as ER4hrl, which has been deposited at the American Type Culture Collection (ATCC), at 12301 Parklawn Drive, Rockville, MD 20852, U.S.A., and is identified by the ATCC No. 55952. It is thought that the above-discussed procedure selectively grows a pre-existing phage that is temperature stable, rather than inducing mutations in the phages to create a temperature-stable phage. In other words, it is thought that the phages labeled 1-5 in Table 1 are actually mixtures of various naturally-occurring, very similar phages, some of which are temperature stable and some of which are not.
The temperature-stable phage ER4hrl is substantially fully stable to exposure to a temperature of 50 °C for 2 hours. This in sharp contrast to the phage 4 of Table 1 from which ER4hrl was derived. Phage 4 would typically lose about 90% of its activity after 2 hours of exposure to a temperature of 50 °C.
It has been found that the temperature-stable phage ER4hrl is also stable for relatively prolonged exposure to pH extremes of 0 to 11. Whereas phage 4 would lose about 90% of its activity after 2 hours of exposure to a pH of either 0 or 11, ER4hrl loses almost no activity during the same amount of exposure to the same pH's.
The pH and temperature stability of ER4hrl could advantageously prolong the useful life of the phage in an animal's digestive tract. Also the pH and temperature stability of ER4hrl could advantageously extend the available methods for transporting ER4hrl. For instance, ER4hrl may better withstand the temperature extremes of unrefrigerated rail-car or truck transport than a phage that had not been temperature treated. Specifically, phages which are temperature treated may be able to better withstand storage at temperatures of 30° C or higher for longer periods than phages which are not temperature treated.
Although the above temperature selection procedure was described for a temperature of 50°C, it will be recognized by persons of ordinary skill in the art that a similar procedure can be utilized for a wide range of temperatures, including, for example, temperatures of 25°C and above. Referring again to Fig. 1, the phages obtained from animal excrement are utilized to reduce a concentration of a bacterium species. Methods by which the phages may be utilized to reduce a concentration of a bacterium species include, for example, applying the phages to surfaces to kill bacterium species on such surfaces. As another example, the phages may be inserted into an animal's digestive tract to reduce a concentration of a bacterium species within the digestive tract. Particular embodiments of the present invention are discussed with reference to Figs. 2-5.
Referring to Fig. 2, a mass 10 comprising a phage is fed to an animal 12 by a handler 14. Mass 10 could comprise, for example, a liquid-filled capsule comprising phages in a liquid medium, or a solid comprising desiccated phages. If the phages are in a liquid medium, the phages can be in, for example, a buffered saline solution comprising about 10 mM MgSO^
In one aspect of the invention, animal 12 is a ruminant, such as a cow, and mass 10 comprises phages selectively lethal to E. coli 0157:H7, such as the phage identified in our lab as ΕR4hrl , and identified by ATCC No. 55952. Ingestion of mass 10 by animal 12 inserts the phages into a digestive tract of animal 12. In applications in which the phages are selectively lethal to
E. coli 0157:H7, the phages will reduce the concentration of E. coli 0157:H7 within the digestive tract of animal 12 without significantly reducing concentrations of other bacteria within the animal's digestive tract. This can advantageously rid an animal of E. coli 0157:H7 without adversely affecting the animal's digestive processes.
Mass 10 can comprise a controlled dosage of a phage . Alternative methods for administering a controlled dosage of a phage to an animal are recognized by persons of ordinary skill in the art, and would include, for example, pouring a dose of a liquid into the mouth of animal 12. As will be recognized by persons of ordinary skill in the art, a phage could be inserted into a digestive tract of animal 12 by methods other than administering a controlled dosage to animal 12.
An alternative method of inserting phages into an animal's digestive tract is illustrated in Figs. 3 and 4. Referring first to Fig. 3, a phage solution 40 is applied to an animal's feed 42. Phage solution 40 will preferably comprise a buffered saline solution, and will more preferably comprise a buffered saline solution containing about 10 mM MgSO^ Alternative methods for applying phages to feed 42 will be recognized by persons of ordinary skill in the art and include, for example, dusting freeze-dried phages onto the feed. Although the phage is shown applied only to a top surface of feed 42, the invention encompasses methods wherein the phage is mixed into feed 42 during or after application to the feed.
Referring next to Fig. 4, feed 42 is ingested by an animal 44, thus inserting phages into animal 44.
A method of the present invention was reduced to practice in an experiment summarized in Table 3. In the experiment, a phage obtained from cattle (genus Bos) feces was utilized to reduce E. coli 0157:H7 concentrations in a digestive tract of a sheep (genus Ovis). The experiment comprised infecting two healthy year-old Suffolk ewes with 4 x 1010 E. coli 0157:H7 strain ATCC 43894 utilizing a procedure described by Kudva et. al. (See, Kudva I. T., Hatfield, P. G ., and Hovde C. J . ( 1995) Applied and Environmental Micro. Vol. 61, pg. 1362-1370.) Specifically, the ewes were orally inoculated with a 20 ml overnight culture of ATCC 43894 in Luria broth using a 20 ml sterile syringe cartridge (no needle). One of the ewes was designated an experimental animal and the other a control animal. Two days after infecting the ewes with E. coli 0157:H7, the experimental animal was given a dose of 2 x 10 of the phage ER4hrl suspended in 20 ml of Luria broth with 10 mM MgSC^, and the other ewe was given Luria broth without phage. The two ewes were maintained on an alfalfa-hay diet throughout the course of the experiment and penned separately.
Table 3
Figure imgf000012_0001
Fecal samples ( 10 gm) were taken at 24 hour intervals for 12 days from both the control animal and the experimental animal. The fecal samples were assayed for the presence of E. coli 0157:H7 before and after enrichment for E. coli 0157:H7, utilizing a procedure described by Kudva et. al. Also, the fecal samples from the experimental animal were assayed for the presence of phage ER4hrl . The procedure utilized for assaying for ER4hrl was as follows. Feces ( 1 gm) were suspended in 10 ml of Luria broth containing 10 mM MgSC>4 with a vortex mixer. The resuspended feces were maintained at 40 °C for 2-4 hours, then spun in a low speed centrifuge to pellet the bacteria and particulate matter, and form a supernatant. Chloroform was added to the supernatant and the supernatant was then filtered through a 0.45 micron filter. About 0.5 ml of the supernatant was plated on a lawn of E. coli 0157:H7 to quantitate the amount of phage present.
Referring to Table 3, Day 0 corresponds to the day on which E. coli were fed to the sheep, and Day 2 corresponds to the day on which phages were fed to the experimental animal. The data shows that the experimental animal cleared E. coli 0157:H7 from its digestive tract four days earlier than the control animal cleared E. coli 0157:H7 from its digestive tract. Clearance of E. coli 0157:H7 from the experimental animal was concomitant with the appearance of phage in the fecal material of the experimental animal, indicating that the phages were responsible for the clearance of E. coli 0157:H7. Also, more phages came out of the experimental animal than had been put into the experimental animal, indicating that the phages had multiplied within the experimental animal. It is noted that the abundance of total coliforms per gram of fecal material remained substantially constant throughout the course of the experiment for both animals (data not shown), indicating that the phage ΕR4hrl is substantially selectively lethal for E. coli 0157 strains. In other words, indicating that the phage ER4hrl is lethal for E. coli 0157 strains and non-lethal for other coliforms.
It is also noted that by Day 11 even the control animal had shed the E. coli 0157:H7 from its system. This evidences that ruminants naturally shed E. coli from their system, a phenomenon known to persons of ordinary skill in the art. However, ruminants also typically get reinfected with E. coli, such as with E. coli 0157:H7. The source of reinfection is typically unknown.
As E. coli 0157 strains are naturally cleared from animal systems and then reestablished in the animal systems, phages specific for E. coli 0157 strains are expected to also be cleared from animal systems after a period of time. Accordingly, such phages may have to be reintroduced into animal digestive tracts at regular intervals to keep the animals clear of E. coli 0157 strains. Alternatively, animals could be cleared of E. coli 0157 strains and at the same time the animals' pens could be cleared of E. coli 0157 by applying phages within the animals' pens. Alternatively, as the most danger of E. coli contamination of animal meat is likely at slaughter, it may be most preferable to insert phages into animal digestive tracts a few days prior to slaughter.
The experiment summarized in Table 3 shows that fecal samples obtained from an animal of a first genus can be utilized to obtain phages for insertion into an animal of a second, different genus. Thus, the present invention encompasses methods in which phages are obtained, for example, from fecal samples of an animal which is to have phages inserted within it; from fecal samples of an animal of the same genus as the animal which is to have phages inserted within it; or from fecal samples of an animal of a different genus than the animal which is to have phages inserted within it.
Another embodiment of the present invention is described with reference to Fig. 5. Fig. 5 illustrates an animal carcass 20 being sprayed with a phage solution 22 by a worker 24 in a meat processing plant. Phage solution 22 is preferably lethal to a bacterium species pathogenic to humans. Application of phage solution 22 to surfaces within the meat processing plant, including animal carcass 20 and surfaces with which animal carcass 20 may come in contact, can reduce a risk of human ingestion of the pathogenic bacterium species. If the phage and a bacterium pathogenic to humans come into proximity with one another, the phage can infect and kill the bacterium. The phage solution can be applied to surfaces either before or after pathogenic bacterium species contact the surface. Also, a phage applied to a surface may leave the surface and ultimately contact a bacterium pathogenic to humans someplace other than the surface.
In a particular aspect of the present invention, phage solution 22 comprises a phage specific for E. coli 0157:H7, such as the phage ER4hrl, identified by the ATCC No. 55952. Application of phage ER4hrl to meat surfaces and to surfaces with which the meat may come in contact can reduce a likelihood of the meat leaving the processing plant contaminated with E. coli 0157:H7. Application of the phage ER4hrl can thus reduce a likelihood of human ingestion of pathogenic E. coli 0157 strains.
It is noted that the present invention encompasses methods beyond those shown in Figs. 2-5. For instance, the method of the present invention encompasses general methods of reducing concentrations of bacterium species on human food items by applying phages lethal to such bacterium species onto surfaces of the food items. Additionally, the present invention encompasses methods for producing dairy products for human consumption in which an animal is milked to produce a dairy product, and phages lethal to a bacterium species are applied to the dairy product. Such methods encompass application of phages to a dairy product to reduce concentrations of pathogenic E. coli 0157 strains within the dairy product. The phages could comprise, for example, ER4hrl .
The invention further encompasses methods for producing meat for human consumption. Such methods can include inserting a phage lethal to a pathogenic bacterium species into a digestive tract of an animal prior to slaughtering the animal. The methods can further include, after slaughtering the animal, applying the phage to the meat obtained from slaughter to help insure that the meat is not contaminated with pathogenic bacterium species introduced onto the meat through mishandling during or after slaughter. Although the animals shown in Figs. 2, 3 and 5 are ruminants, it is to be understood that the method of the present invention can be used for treating any animal, including, for example, swine and poultry.
The invention further encompasses methods of utilizing phages for reducing pathogenic Salmonella contamination of food products, such as, for example, poultry products. Such phages could be obtained from, for example, poultry manure.
The invention encompasses methods of utilizing phages for reducing pathogenic bacterial contamination of plant products, such as, for example, fruit and vegetable products. An example fruit product is apple juice. An example vegetable product is lettuce leaves.
Experiments have been conducted to demonstrate the applicability of a method of the present invention for reducing bacterial contamination of plant products. Specifically, leaf lettuce was inoculated with E. coli 0157:H7 by submerging the leaves in a saline solution having 10 colony forming units (cfu) of E. coli 0157:H7 per ml. The leaf lettuce was incubated in the saline solution for 10 minutes, which resulted in approximately 10 cfu being deposited per gram of lettuce. Lettuce leaves were removed from the saline solution and placed in either SM (Suspension Medium comprising 0.1 M NaCl; 0.01 M Mg(S04); 2% gelatin; and 1 M Tris-HCl, pH 7.5) without phage (control) or SM with phage (experiment). The SM with phage contained 10 plaque -forming units (pfu) of the 0157-specific phage ER4hrl . After 6 hours of incubation, the lettuce leaves incubated with phage had 10-fold less E. coli 0157:H7 than did the control lettuce leaves. In addition, 1000 times less E. coli 0157:H7 was present in the SM having phage than in the control SM. These experimental findings support the concept that phages can be utilized to reduce bacterial contamination of plant products.
The invention further encompasses methods of utilizing phages for specific identification of bacterial pathogens. For instance, as the phages labeled 1, 3, 4 and 5 in Table 1 are relatively specific for utilizing E. coli 0157 strains as hosts, such phages may be used to identify the presence of E. coli 0157 strains. ΕR4hrl is also relatively specific for utilizing E. coli 0157 strains as hosts, and can therefore also be utilized to identify E. coli 0157:H7 strains.
An example method for utilizing an phage specific for an E. coli strain to identify the E. coli strain is described by Bonner and Cliver. (See, Bonner
A. B. and Cliver D . O . (1990) Isolation and Characterization of a Coliphage
Specific for Escherichia coli Q 157:H7, Journal of Food Protection, pgs. 944-947.)
The method of Bonner and Cliver is an in vitro method for detecting E. coli 0157:H7. The present invention encompasses an in vivo method for detecting E. coli 0157:H7. Specifically, the invention encompasses a method wherein a phage specific for E. coli 0157:H7 is inserted into an animal's digestive tract and the animal's feces are subsequently monitored to determine if the phage multiplies within the animal. If the phage multiplies, more phage will come out of the animal then was inserted into the animal. If the phage is specific for E. coli 0157:H7, such multiplication of the phage within the animal will indicate the presence of E. coli 0157:H7 within the animal.
An advantage of the in vivo method of the present invention over the in vitro method of Bonner and Cliver is that the method of the present invention can eradicate E. coli 0157:H7 from an animal while the method is being utilized to detect E. coli 0157:H7. Thus, the method can provide information that an animal is carrying E. coli 0157:H7 and, in a common step, reduce a concentration of E. coli 0157:H7 within the animal.
The above-described method of in vivo detection can be utilized for other pathogens in addition to E. coli 0157:H7. For instance, the method can be utilized for detection of E. coli 0111 strains, and Salmonella strains, including, for example, S. enteritidis, S. typhi, S. paratyphi, S. d blin, S. cholerasuis , and S. pullorum .
The invention further encompasses methods in which phages are utilized in increasingly high concentrations to compensate for natural selection of bacteria resistant to the phages. For example, a phage could be administered to an animal at a first dose to reduce a concentration of a bacterial strain within the animal. Subsequently, the phage could be readministered to the animal at a second dose to reduce a concentration of the bacterial strain that may have reestablished in the animal. The second dose could be at the same concentration as the first dose, a lower concentration than the first dose, or a higher concentration than the first dose. Preferably, if there is evidence that the bacterial strain has acquired resistance to the phage the second dose will be at a higher concentration than the first dose. The doses of phage could comprises mixtures, either solid or liquid, containing the phage at desired concentrations. The invention further encompasses methods in which two or more genetically different phages are utilized, either sequentially or simultaneously, to reduce concentrations of one or more pathogenic bacteria. For instance, at least two genetically different phages selective for E. coli 0157:H7 could be mixed to form a phage cocktail. The genetically different phages could comprise, for instance, two of the phages labeled 1, 4 or 5 in tables 1 and 2. (The phage labeled 3 was not included in the list of genetically different phages because the phage labeled 3 showed the same growth patterns as the phage labeled 1 in the experiment summarized in Table 2. Accordingly, is not clear if the phages labeled 1 and 3 are genetically different from one another.) The phage cocktail could then be inserted within an animal's digestive tract to substantially simultaneously insert the at least two different phages. Alternatively, the at least two different phages could be inserted sequentially, with one of the phages being inserted first, a period of time passing, and then another of the phages being inserted. Two or more different phages could also be applied, either simultaneously or sequentially, to one or more surfaces to reduce a concentration of a bacterium species pathogenic to humans. For instance, two or more different phages could be applied to one or more surfaces in a meat processing plant.
Utilization of two or more different phages in a method for reducing a concentration of a bacterial strain can have advantages over methods which utilize only one phage. For instance, bacterial strains are less likely to develop resistance to a cocktail comprising two or more different phages then to develop resistance to a single phage. Further, if two or more different phages are applied sequentially, rather than simultaneously, a later-applied phage can remain lethal to bacteria which have developed a resistance to an earlier-applied phage.
It is noted that phages are frequently relatively unstable to prolonged exposure to ultraviolet light. Accordingly, the invention encompasses methods of protecting phages from ultraviolet light prior to, and during, utilization of the phages to destroy pathogenic bacteria. Methods for protecting the phages from ultraviolet light can include, for example, storing the phages in containers which are relatively ultraviolet-light-impermeable, applying the phages to animal feed in darkened areas, and incorporating the phages within capsules having relatively ultraviolet-light-impermeable outer casings.

Claims

1. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising inserting a phage lethal to the bacterium species into an animal's digestive tract.
2. The method of claim 1 wherein the animal is a non-human animal.
3. The method of claim 1 wherein the phage is inserted into the animal's digestive tract by applying the phage to a feed which is thereafter ingested by the animal.
4. The method of claim 1 wherein the phage is inserted into the animal's digestive tract by administering the phage to the animal as a controlled dosage .
5. The method of claim 1 wherein the animal is a ruminant.
6. The method of claim 1 wherein the animal is a bird.
7. The method of claim 1 wherein the animal is a pig.
8. A method of reducing a concentration of a bacterium species within an animal's digestive tract comprising: collecting a sample of naturally-occurring phages; obtaining a phage lethal to the undesired bacterium species from the sample ; and inserting the phage within the animal's digestive tract.
9. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising the following steps: collecting animal excrement; obtaining a phage lethal to the bacterium species from the animal excrement; and inserting the phage into a digestive tract of an animal to reduce a concentration of the bacterium species within the digestive tract.
10. The method of claim 9 wherein the phage lethal to the bacterium species is lethal to the bacterium species and non-lethal to other bacteria which naturally occur within the digestive tract and wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host; and testing the phages which can utilize the bacterium species as a host to determine which of the phages which can utilize the bacterium species as a host are lethal to the bacterium species and also non-lethal to other bacteria which can naturally occur within the digestive tract of the animal.
11. The method of claim 10 wherein the phage is non-lethal to all bacteria which naturally occur within the digestive tract and which are not the bacterium species pathogenic to humans.
12. The method of claim 9 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host, the growth conditions comprising temperatures above 25° C.
13. The method of claim 9 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host, the growth conditions comprising temperatures of at least 50° C.
14. The method of claim 9 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; applying growth conditions to the mix of phages to selectively grow those 5 phages within the mix of phages which can utilize the bacterium species as a host, the growth conditions comprising temperatures of at least 50° C; and wherein the method further comprises, before inserting the phage into the digestive tract, storing the phage for some period of time at a temperature of 30° C or higher. w
15. The method of claim 9 wherein the animal from which the excrement is collected is the same as the animal into which the phage is inserted.
15 16. The method of claim 9 wherein the excrement is collected from a first animal and inserted into a second animal, the first and second animals belonging to a common genus.
17. The method of claim 9 wherein the excrement is collected from a 0 first animal and inserted into a second animal, the first and second animals belonging to different genera.
18. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising inserting two genetically different phages
25 lethal to the bacterium species into an animal's digestive tract.
19. The method of claim 18 wherein the two different phages are inserted substantially simultaneously.
30 20. The method of claim 18 wherein the two different phages are inserted sequentially.
21. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising: inserting a first mixture into an animal's digestive tract, the first mixture comprising a first concentration of a phage lethal to the bacterium species; and after inserting the first mixture into the animal's digestive tract, inserting a second mixture into the animal's digestive tract, the second mixture comprising a second concentration of the phage lethal to the bacterium species, the second concentration being greater than the first concentration.
22. A method for reducing a concentration of a bacterium species pathogenic to humans comprising: applying a phage lethal to the bacterium species on a surface; and providing a phage from the surface and a bacterium pathogenic to humans in proximity to each other to infect the bacterium with the phage.
23. The method of claim 22 further comprising, before applying the phage on the surface, obtaining the phage from an excrement of an animal.
24. The method of claim 22 further comprising, before applying the phage on the surface, obtaining the phage from an excrement of a non-human animal.
25. The method of claim 22 wherein the surface comprises meat and wherein the bacterium species is E. coli 0157:H7.
26. The method of claim 22 wherein the surface comprises a plant surface and wherein the bacterium species is E. coli 0157:H7.
27. The method of claim 22 wherein the surface comprises an edible surface of a plant.
28. The method of claim 22 wherein the surface comprises an edible surface of a plant and wherein the bacterium species is E. coli 0157:H7.
29. The method of claim 22 wherein the surface comprises a lettuce leaf and wherein the bacterium species is E. coli 0157:H7.
30. A method for reducing a concentration of a bacterium species within a meat processing plant comprising applying a phage lethal to the bacterium species to at least one surface within the meat processing plant.
31. A method for reducing a concentration of a bacterium species on a human food item comprising applying a phage lethal to the bacterium species to a surface of the food item.
32. The method of claim 1 , 9, 22, 30 or 31 wherein the bacterium species is a pathogenic coliform.
33. The method of claim 1 , 9, 30 or 31 wherein the bacterium species is a pathogenic form of Salmonella.
34. The method of claim 31 wherein the food item comprises a plant.
35. The method of claim 31 wherein the food item comprises a vegetable .
36. The method of claim 31 wherein the food item comprises a vegetable, the bacterium species is E. coli 0157:H7, and the phage is that identified by ATCC number 55952.
37. The method of claim 31 wherein the food item comprises meat, the bacterium species is E. coli 0157:H7, and the phage is that identified by ATCC number 55952.
38. A method for selectively reducing a concentration of a bacterium species pathogenic to humans which is a natural part of the bacterial flora of an animal digestive tract comprising the following steps: collecting animal excrement; obtaining a phage lethal to the bacterium species from the animal excrement; applying the phage lethal to the bacterium species to a surface; and providing a phage from the surface and a bacterium pathogenic to humans in proximity to each other to infect the bacterium with the phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface.
39. The method of claim 9 or 38 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host.
40. The method of claim 38 wherein said surface is on a human food.
41. The method of claim 38 wherein the step of applying the phage to said surface comprises spraying the phage on meat and other surfaces within a meat processing plant.
42. The method of claim 38 wherein the animal is a ruminant, the bacterium species is E. coli 0157:H7, and the isolated phage is that identified by ATCC number 55952.
43. A method for selectively reducing a concentration of a bacterium species comprising the following steps: obtaining a first phage lethal to the bacterium species; obtaining a second phage lethal to the bacterium species, the second phage being genetically different than the first phage; applying the first phage lethal to the bacterium species and the second phage lethal to the bacterium species to a surface; and providing at least one of the first or second phage from the surface and a bacterium of the bacterium species in proximity to each other to infect the bacterium with the at least one of the first or second phage and to reduce a concentration of the bacterium species.
44. A method for selectively reducing a concentration of a bacterium species pathogenic to humans which is a natural part of the bacterial flora of an animal digestive tract comprising the following steps: collecting animal excrement; obtaining a first phage lethal to the bacterium species from the animal excrement; obtaining a second phage lethal to the bacterium species from the animal excrement, the second phage being genetically different than the first phage; applying the first phage lethal to the bacterium species to a surface; providing a first phage from the surface and a bacterium pathogenic to humans in proximity to each other to infect the bacterium with the first phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface; applying the second phage lethal to the bacterium species to the surface; and providing a second phage from the surface and a bacterium pathogenic to humans in proximity to each other to infect the bacterium with the second phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface.
45. The method of claim 44 wherein the first phage and the second phage are applied substantially simultaneously to the surface.
46. The method of claim 44 wherein the second phage is applied to the surface after the first phage is applied to the surface.
47. A method for selectively reducing a concentration of a bacterium species pathogenic to humans which is a natural part of the bacterial flora of an animal digestive tract comprising the following steps: collecting animal excrement; obtaining a phage lethal to the bacterium species from the animal excrement; applying the first phage lethal to the bacterium species to a surface, the phage being applied to a first concentration; after applying the phage to a first concentration, reapplying the phage to the surface to a second concentration, the second concentration being greater than the first concentration; and providing a phage from the surface and a bacterium pathogenic to humans in proximity to each other to infect the bacterium with the phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface .
48. A method for producing meat for human consumption comprising the following steps: inserting a phage lethal to a bacterium species into a digestive tract of an animal to reduce a concentration of the bacterium species within the digestive tract; and slaughtering the animal and producing meat therefrom for human consumption.
49. The method of claim 48 further comprising, after slaughtering the animal, applying the phage lethal to the bacterium species to the meat.
50. The method of claim 9 or 48 wherein the animal is a ruminant and the bacterium species is a pathogenic coliform.
51. The method of claim 9 or 48 wherein the animal is a bird and the bacterium species is a pathogenic form of Salmonella.
52. A method for producing meat for human consumption comprising the following steps: slaughtering an animal and producing meat therefrom; and applying a phage lethal to a bacterium species to the meat.
53. The method of claim 38 or 52 wherein the animal is a ruminant and the bacterium species is a pathogenic strain of E. coli 0157.
54. A method for producing dairy products for human consumption comprising the following steps: milking an animal to produce a dairy product; and applying a phage lethal to a bacterium species to the dairy product.
55. The method of claim 1, 9, 22, 30, 31, or 54 wherein the bacterium species is E. coli 0157:H7 and wherein the phage is that identified by ATCC number 55952.
56. A method for producing plant products for human consumption comprising applying a phage lethal to a bacterium species to the plant products.
57. The method of claim 48, 52, 54, or 56 further comprising: collecting animal excrement; and obtaining the phage lethal to the bacterium species from the excrement.
58. The method of claim 56 wherein the plant products are fruit products.
59. The method of claim 56 wherein the plant products are vegetable products.
60. The method of claim 56 wherein the plant products comprise lettuce leaves.
61. A method for selectively reducing a concentration of a bacterium species within a first animal digestive tract comprising the following steps: obtaining excrement from a second animal, the second animal being a different genus than the first animal; obtaining a phage lethal to the bacterium species from the excrement; and providing the phage lethal to the bacterium species within the digestive tract of the first animal to reduce the concentration of the bacterium species within the first animal digestive tract.
62. The method of claim 61 wherein the first animal is a cow and the second animal is a sheep.
63. A method of growing phage comprising the following steps: growing a culture of a host bacteria species to an exponential growth phase; and while the culture of host bacteria species is at the exponential growth phase, inoculating the culture with an inoculant comprising an inoculating phage.
64. The method of claim 63 wherein the inoculating phage is in a substantially purified form.
65. The method of claim 63 wherein the inoculating phage is in a substantially unpurified form.
66. The method of claim 63 further comprising: prior to inoculating, purifying the inoculating phage from a contaminant.
67. The method of claim 63 wherein the inoculant comprises feces.
68. A method of detecting a bacterial strain in vivo within an animal comprising: obtaining a phage which selectively utilizes the bacterial strain as a host; inserting the phage into the digestive tract of an animal; and determining if the phage multiplies within the animal.
69. The method of claim 68 wherein the obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host.
70. The method of claim 68 wherein the determining if the phage multiplies within the animal comprises determining an amount of phage excreted by the animal.
71. The method of claim 68 wherein the bacterial strain is E. coli 0157:H7.
72. A method of detecting a bacterial strain in vivo within an animal which comprises, in a common step, both detecting the bacterial strain and reducing a concentration of the bacterial strain within the animal.
73. A substantially purified phage identified as ER4hrl and by ATCC number 55952.
AMENDED CLAIMS
[received by the International Bureau on 28 September 1998 (28.09.98); original claims 1-73 replaced by amended claims 1-45 (7 pages)]
1. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising inserting a phage lethal to the bacterium species into a non-human animal's digestive tract, the bacterium species being non-pathogenic to the non-human animal.
2. The method of claim 1 wherein the phage is inserted into the animal's digestive tract by applying the phage to a feed which is thereafter ingested by the animal.
3. The method of claim 1 wherein the phage is inserted into the animal's digestive tract by administering the phage to the animal as a controlled dosage.
4. The method of claim 1 wherein the animal is a ruminant.
5. The method of claim 1 wherein the animal is a bird.
6. The method of claim 1 wherein the animal is a pig.
7. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising the following steps: collecting excrement from an animal; obtaining a phage lethal to the bacterium species from the excrement; inserting the phage into a digestive tract of a non-human animal to reduce a concentration of the bacterium species within the digestive tract of the non-human animal; and wherein the bacterium species is non-pathogenic to the non-human animal.
8. The method of claim 7 wherein the phage lethal to the bacterium species is lethal to the bacterium species and non-lethal to other bacteria which naturally occur within the digestive tract and wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host; and testing the phages which can utilize the bacterium species as a host to determine which of the phages which can utilize the bacterium species as a host are lethal to the bacterium species and also non-lethal to other bacteria which can naturally occur within the digestive tract of the animal.
9. The method of claim 7 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host, the growth conditions comprising temperatures above 25° C.
10. The method of claim 7 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host, the growth conditions comprising temperatures of at least 50° C.
11. The method of claim 7 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host, the growth conditions comprising temperatures of at least 50° C; and wherein the method further comprises, before inserting the phage into the digestive tract, storing the phage for some period of time at a temperature of 30° C or higher.
12. The method of claim 7 wherein the animal from which the excrement is collected is the same as the animal into which the phage is inserted.
13. The method of claim 7 wherein the excrement is collected from a first animal and inserted into a second animal, the first and second animals belonging to a common genus.
14. The method of claim 7 wherein the excrement is collected from a first animal and inserted into a second animal, the first and second animals belonging to different genera.
15. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising inserting two genetically different phages lethal to the bacterium species into an non-human animal's digestive tract, wherein the bacterium species is non-pathogenic to the non-human animal.
16. The method of claim 15 wherein the two different phages are inserted substantially simultaneously.
17. The method of claim 15 wherein the two different phages are inserted sequentially.
18. A method for selectively reducing a concentration of a bacterium species pathogenic to humans comprising: inserting a first mixture into an animal's digestive tract, the first mixture comprising a first concentration of a phage lethal to the bacterium species, the bacterium species being non-pathogenic to the animal; and after inserting the first mixture into the animal's digestive tract, inserting a second mixture into the animal's digestive tract, the second mixture comprising a second concentration of the phage lethal to the bacterium species, the second concentration being greater than the first concentration.
19. A method for reducing a concentration of a bacterium species pathogenic to humans comprising: applying a phage lethal to the bacterium species on a non-food surface ; and providing a phage from the surface and a bacterium pathogenic to humans in proximity to each other to infect the bacterium with the phage .
20. The method of claim 19 further comprising, before applying the phage on the surface, obtaining the phage from an excrement of an animal.
21. The method of claim 19 further comprising, before applying the phage on the surface, obtaining the phage from an excrement of a non-human animal.
22. A method for reducing a concentration of a bacterium species within a meat processing plant comprising applying a phage lethal to the bacterium species to at least one surface within the meat processing plant.
23. The method of claim 1 , 7, 19 or 22 wherein the bacterium species is a pathogenic coliform.
24. The method of claim 1 , 7, or 22 wherein the bacterium species is a pathogenic form of Salmonella.
25. The method of claim 1 , 7, 19 or 22 wherein the bacterium species is E. coli 0157:H7 and wherein the phage is that identified by ATCC number 55952.
26. A method for selectively reducing a concentration of a bacterium species pathogenic to humans which is a natural part of the bacterial flora of an animal digestive tract and non-pathogenic to the animal, the method comprising: collecting excrement from the animal; obtaining a phage lethal to the bacterium species from the animal excrement; applying the phage lethal to the bacterium species to a surface; and providing a phage from the surface and the bacterium pathogenic to humans in proximity to each other to infect the bacterium with the phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface.
27. The method of claim 7 or 26 wherein the step of obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host.
28. The method of claim 26 wherein said surface is on a human food.
29. The method of claim 26 wherein the step of applying the phage to said surface comprises spraying the phage on meat and other surfaces within a meat processing plant.
30. The method of claim 26 wherein the animal is a ruminant, the bacterium species is E. coli 0157:H7, and the isolated phage is that identified by ATCC number 55952.
31. The method of claim 26 wherein the animal is a ruminant and the bacterium species is a pathogenic strain of E. coli 0157.
32. A method for selectively reducing a concentration of a bacterium species pathogenic to humans which is a natural part of the bacterial flora of an animal digestive tract and non-pathogenic to the animal, comprising: collecting excrement from the animal; obtaining a first phage lethal to the bacterium species from the excrement; obtaining a second phage lethal to the bacterium species from the excrement, the second phage being genetically different than the first phage; applying the first phage lethal to the bacterium species to a surface; providing a first phage from the surface and the bacterium pathogenic to humans in proximity to each other to infect the bacterium with the first phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface; applying the second phage lethal to the bacterium species to the surface; and providing a second phage from the surface and the bacterium pathogenic to humans in proximity to each other to infect the bacterium with the second phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface.
33. The method of claim 32 wherein the first phage and the second phage are applied substantially simultaneously to the surface.
34. The method of claim 32 wherein the second phage is applied to the surface after the first phage is applied to the surface.
35. A method for selectively reducing a concentration of a bacterium species pathogenic to humans which is a natural part of the bacterial flora of an animal digestive tract and non-pathogenic to said animal, comprising: collecting excrement from the animal; obtaining a phage lethal to the bacterium species from the animal excrement; applying the first phage lethal to the bacterium species to a surface, the phage being applied to a first concentration; after applying the phage to a first concentration, reapplying the phage to the surface to a second concentration, the second concentration being greater than the first concentration; and providing a phage from the surface and the bacterium pathogenic to humans in proximity to each other to infect the bacterium with the phage and to reduce a concentration of the bacterium species pathogenic to humans on said surface.
36. A method for producing meat for human consumption comprising the following steps: inserting a phage lethal to a bacterium species into a digestive tract of an animal to reduce a concentration of the bacterium species within the digestive tract, the bacterium species being pathogenic to humans and non-pathogenic to the animal; and slaughtering the animal and producing meat therefrom for human consumption.
37. The method of claim 36 further comprising, after slaughtering the animal, applying the phage lethal to the bacterium species to the meat.
38. The method of claim 7 or 36 wherein the animal is a ruminant 5 and the bacterium species is a pathogenic coliform.
39. The method of claim 7 or 36 wherein the animal is a bird and the bacterium species is a pathogenic form of Salmonella.
W 40. The method of claim 36 further comprising: collecting animal excrement; and obtaining the phage lethal to the bacterium species from the excrement.
41. A method of detecting a bacterial strain in vivo within an animal 15 comprising: obtaining a phage which selectively utilizes the bacterial strain as a host; inserting the phage into the digestive tract of an animal; and determining if the phage multiplies within the animal.
20 42. The method of claim 41 wherein the obtaining the phage comprises: procuring a mix of phages from the animal excrement; and applying growth conditions to the mix of phages to selectively grow those phages within the mix of phages which can utilize the bacterium species as a host.
25
43. The method of claim 41 wherein the determining if the phage multiplies within the animal comprises determining an amount of phage excreted by the animal.
30 AA. The method of claim 41 wherein the bacterial strain is E. coli
0157:H7.
45. A method of detecting a bacterial strain in vivo within an animal which comprises, in a common step, both detecting the bacterial strain and 35 reducing a concentration of the bacterial strain within the animal.
PCT/US1998/007395 1997-04-24 1998-04-13 Phages, methods for growing and detecting them and their use WO1998047521A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71133/98A AU7113398A (en) 1997-04-24 1998-04-13 Phages, methods for growing and detecting them and their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84550797A 1997-04-24 1997-04-24
US08/845,507 1997-04-24
US99403797A 1997-12-18 1997-12-18
US08/994,037 1997-12-18

Publications (1)

Publication Number Publication Date
WO1998047521A1 true WO1998047521A1 (en) 1998-10-29

Family

ID=27126582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007395 WO1998047521A1 (en) 1997-04-24 1998-04-13 Phages, methods for growing and detecting them and their use

Country Status (2)

Country Link
AU (1) AU7113398A (en)
WO (1) WO1998047521A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001050866A2 (en) * 2000-01-11 2001-07-19 Intralytix, Inc. Method and device for sanitation using bacteriophages
WO2002086154A2 (en) * 2001-04-19 2002-10-31 Biophage, Inc. Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages
WO2003054173A1 (en) * 2001-12-13 2003-07-03 Societe Des Produits Nestle S.A. Isolated phages and their use in food or pet food products
EP1883304A1 (en) * 2005-05-26 2008-02-06 Gangagen Life Sciences Inc. Process for treating animal waste
US7807149B2 (en) 2003-07-23 2010-10-05 Biocontrol Limited Bacteriophage-containing therapeutic agents
US8475787B2 (en) 2007-03-09 2013-07-02 Bio-Control Limited Beneficial effects of bacteriophage treatments
US9277763B2 (en) 2013-06-27 2016-03-08 Starbucks Corporation Biopreservation methods for beverages and other foods
EP4298910A1 (en) * 2022-06-30 2024-01-03 Lesaffre et Compagnie Microcapsule comprising a bacteriophage

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004326A1 (en) * 1986-12-01 1988-06-16 Mcdonnell Douglas Corporation Method of identifying unknown organisms
EP0290295A2 (en) * 1987-05-07 1988-11-09 Microbial Developments Limited Antimicrobial Preparations
EP0403292A2 (en) * 1989-06-14 1990-12-19 Microbial Developments Limited Ruminant feedstuff additives
EP0414304A2 (en) * 1989-08-21 1991-02-27 Unilever N.V. Aqueous antibacterial compositions comprising surfactant and bacteriophage
WO1998008944A1 (en) * 1996-08-26 1998-03-05 Bio Venture Bank Co., Ltd. Novel bacteriophage, method for screening the same, novel biobactericidal materials prepared with the use of the same, and reagent for detecting the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004326A1 (en) * 1986-12-01 1988-06-16 Mcdonnell Douglas Corporation Method of identifying unknown organisms
EP0290295A2 (en) * 1987-05-07 1988-11-09 Microbial Developments Limited Antimicrobial Preparations
EP0403292A2 (en) * 1989-06-14 1990-12-19 Microbial Developments Limited Ruminant feedstuff additives
EP0414304A2 (en) * 1989-08-21 1991-02-27 Unilever N.V. Aqueous antibacterial compositions comprising surfactant and bacteriophage
WO1998008944A1 (en) * 1996-08-26 1998-03-05 Bio Venture Bank Co., Ltd. Novel bacteriophage, method for screening the same, novel biobactericidal materials prepared with the use of the same, and reagent for detecting the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.B. RONNER ET AL.: "ISOLATION AND CHARACTERIZATION OF A COLIPHAGE SPECIFIC FOR ESCHERICHIA COLI 0157:H7", JOURNAL OF FOOD PROTECTION, vol. 53, no. 11, November 1990 (1990-11-01), AMES, IA, US, pages 944 - 947, XP002073167 *
DATABASE WPI Section Ch Week 9820, Derwent World Patents Index; Class D13, AN 98-230262, XP002072584 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001050866A3 (en) * 2000-01-11 2002-02-07 Intralytix Inc Method and device for sanitation using bacteriophages
US6699701B1 (en) 2000-01-11 2004-03-02 Intralytix, Inc. Method and device for sanitation using bacteriophages
EP1421855A2 (en) * 2000-01-11 2004-05-26 Intralytix Inc. Method and device for sanitation using bacteriophages
EP1421855A3 (en) * 2000-01-11 2004-07-14 Intralytix Inc. Method and device for sanitation using bacteriophages
WO2001050866A2 (en) * 2000-01-11 2001-07-19 Intralytix, Inc. Method and device for sanitation using bacteriophages
WO2002086154A2 (en) * 2001-04-19 2002-10-31 Biophage, Inc. Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages
WO2002086154A3 (en) * 2001-04-19 2003-07-10 Biophage Inc Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages
US7951575B2 (en) 2001-12-13 2011-05-31 Nestec S.A. Isolated phages and their use in food or pet food products
WO2003054173A1 (en) * 2001-12-13 2003-07-03 Societe Des Produits Nestle S.A. Isolated phages and their use in food or pet food products
US7211426B2 (en) 2001-12-13 2007-05-01 Nestec S.A. Isolated phages and their use in food or pet food products
US8021657B2 (en) 2001-12-13 2011-09-20 Nestec S.A. Isolated phages and their use in food or pet food products
US8388946B2 (en) 2003-07-23 2013-03-05 Biocontrol Limited Bacteriophage-containing therapeutic agents
US7807149B2 (en) 2003-07-23 2010-10-05 Biocontrol Limited Bacteriophage-containing therapeutic agents
US8105579B2 (en) 2003-07-23 2012-01-31 Biocontrol Limited Bacteriophage-containing therapeutic agents
US9687514B2 (en) 2003-07-23 2017-06-27 Biocontrol Limited Bacteriophage-containing therapeutic agents
EP1883304A4 (en) * 2005-05-26 2009-12-09 Chr Hansen As Process for treating animal waste
EP1883304A1 (en) * 2005-05-26 2008-02-06 Gangagen Life Sciences Inc. Process for treating animal waste
US8475787B2 (en) 2007-03-09 2013-07-02 Bio-Control Limited Beneficial effects of bacteriophage treatments
US9277763B2 (en) 2013-06-27 2016-03-08 Starbucks Corporation Biopreservation methods for beverages and other foods
EP4298910A1 (en) * 2022-06-30 2024-01-03 Lesaffre et Compagnie Microcapsule comprising a bacteriophage
WO2024003265A1 (en) * 2022-06-30 2024-01-04 Lesaffre Et Compagnie Microcapsule comprising a bacteriophage

Also Published As

Publication number Publication date
AU7113398A (en) 1998-11-13

Similar Documents

Publication Publication Date Title
US10265353B2 (en) Enterohemorrhagic E. coli bacteriophage Esc-CHP-1 and use thereof for inhibiting proliferation of enterohemorrhagic E. coli
US20020090356A1 (en) Use of bacteriophages for control of escherichia coli 0 157
EP1337626B1 (en) Bacteriophage composition useful in treating food products to prevent bacterial contamination
Brashears et al. Antagonistic action of Lactobacillus lactis toward Salmonella spp. and Escherichia coli O157: H7 during growth and refrigerated storage
Hilmarsson et al. Effect of glycerol monocaprate (monocaprin) on broiler chickens: an attempt at reducing intestinal Campylobacter infection
Kwiatek et al. Prevalence and distribution of Campylobacter spp. on poultry and selected red meat carcasses in Poland
Russell et al. Potential effect of cattle diets on the transmission of pathogenic Escherichia coli to humans
AU2002238795A1 (en) Bacteriophage composition useful in treating food products to prevent bacterial contamination
Aho et al. Competitive exclusion of campylobacters from poultry with K-bacteria and Broilact®
dos Reis Tassinari et al. Incidence of Yersinia spp. in food in Sao Paulo, Brazil
Reynolds et al. Evaluation of combined antibiotic and competitive exclusion treatment in broiler breeder flocks infected with Salmonella enterica serovar Enteritidis
Ngene et al. Bacteriophages as Bio-control agent against Food-Borne Pathogen E. coli O157: H7
WO1998047521A1 (en) Phages, methods for growing and detecting them and their use
Hume et al. Reduction of caecal Listeria monocytogenes in Leghorn chicks following treatment with a competitive exclusion culture (PREEMPT™)
US5302388A (en) Control of campylobacter jejuni colonization
Sveum et al. Recovery of salmonellae from foods using a combined enrichment technique
KR101830900B1 (en) Novel avian pathogenic Escherichia coli specific bacteriophage EC13 and antibacterial composition comprising the same
Promsopone et al. Evaluation of an avian-specific probiotic and Salmonella typhimurium-specific antibodies on the colonization of Salmonella typhimurium in broilers
Mulder et al. Experience with competitive exclusion in the Netherlands
Notermans et al. The effect of cultural procedures on the attachment of bacteria to chicken breast meat
Windayani et al. Antibacterial activity of colostrum kefir against foodborne pathogen bacteria
US7491387B2 (en) Disinfection of foodstuffs
福島博 Yersinia enterocolitica serotype 03 in naturally infected raw pork.
Cox et al. Pathogens associated with processed poultry
FAZZA et al. Non Typhoidal Salmonella in food products

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998546124

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA